More Progress in Vaccines to Reduce Covid Transmission (NextGen Vax Update 28)

['Hilda Bastian', '.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright'] Absolutely Maybe 2025-04-30 00:00:00

There are some clinical trial results for a couple of other vaccines, and 9 other preclinical studies – including several other vaccines showing protection against transmission. It’s a viral vector vaccine based on adenovirus that was developed by Washington University in St Louis (USA), and manufactured by Bharat Biotech in India. 33 mucosal vaccines have reached clinical trial, although some of the vaccines are no longer in development. I discussed one of them above – the intranasal vaccine hoping to provide sarbecovirus protection developed the National University of Singapore. Convidecia (China), inhaled viral vector vaccine: China (September 2022), Morocco (November 2022), Indonesia (March 2023).